These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35951243)

  • 1. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
    Wang Y; Luangasanatip N; Pan-Ngum W; Isaranuwatchai W; Prawjaeng J; Saralamba S; Painter C; Briones JR; Teerawattananon Y
    Eur J Health Econ; 2023 Jul; 24(5):735-748. PubMed ID: 35951243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures.
    Botwright S; Win EM; Kapol N; Benjawan S; Teerawattananon Y
    Pharmacoeconomics; 2023 Jan; 41(1):77-91. PubMed ID: 36348154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
    Jentsch PC; Anand M; Bauch CT
    Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
    Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
    BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
    Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
    BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who should be prioritized for COVID-19 vaccination in China? A descriptive study.
    Yang J; Zheng W; Shi H; Yan X; Dong K; You Q; Zhong G; Gong H; Chen Z; Jit M; Viboud C; Ajelli M; Yu H
    BMC Med; 2021 Feb; 19(1):45. PubMed ID: 33563270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.
    Orangi S; Ojal J; Brand SP; Orlendo C; Kairu A; Aziza R; Ogero M; Agweyu A; Warimwe GM; Uyoga S; Otieno E; Ochola-Oyier LI; Agoti CN; Kasera K; Amoth P; Mwangangi M; Aman R; Ng'ang'a W; Adetifa IM; Scott JAG; Bejon P; Keeling MJ; Flasche S; Nokes DJ; Barasa E
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35914832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in preventive behaviour after COVID-19 vaccination in Thailand: a cross-sectional study.
    Ngamchaliew P; Kaewkuea N; Nonthasorn N; Vonnasrichan T; Rongsawat N; Rattanachai L; Chaipipattanakij W; Kamolnawin S; Vichitkunakorn P
    BMC Public Health; 2022 Nov; 22(1):2039. PubMed ID: 36348474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis.
    Kelso JK; Halder N; Milne GJ
    BMC Infect Dis; 2013 Feb; 13():81. PubMed ID: 23398722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual preferences for COVID-19 vaccination in China.
    Leng A; Maitland E; Wang S; Nicholas S; Liu R; Wang J
    Vaccine; 2021 Jan; 39(2):247-254. PubMed ID: 33328140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
    Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
    BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
    Front Immunol; 2022; 13():919408. PubMed ID: 35935993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.